FDA Approves First At-Home Transcranial Direct Current Stimulation (tDCS) Treatment for Depression

Flow Neuroscience has launched FL-100 in the U.S., marking the first FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for moderate to severe major depressive disorder. This prescription-only device offers clinicians a new modality for patients, either as a standalone therapy or alongside medication, addressing a significant public health challenge.